Abstract
OBJECTIVE--To determine how many lives would be saved if patients were routinely treated with ACE inhibitors after myocardial infarction according to the criteria of four recent major clinical trials, and to estimate the costs and benefits of these approaches. DESIGN--Retrospective survey. SETTING--The Nottingham Health District. PATIENTS--Data from 7855 patients admitted between 1989 and 1990 were combined and the selection criteria of four major clinical trials (AIRE, SAVE, GISSI-3, and ISIS-4) were applied. RESULTS--Of the patients admitted in Nottingham with confirmed myocardial infarcts 39% were eligible for AIRE and 8% for SAVE. In patients with suspected myocardial infarction as defined by the major trials, 60% would have been eligible for GISSI-3 and 63% for ISIS-4. Treating appropriate patients in accordance with these trials would have saved 20 (AIRE), 3 (SAVE), 4 (GISSI-3) and 5 (ISIS-4) lives each year in Nottingham at a drug cost of 5400 pounds, 33 pounds 791, 2730 pounds, and 4116 pounds per life per year saved respectively. CONCLUSIONS--Short-term treatment with ACE inhibition appears to be cheaper but such an approach would save fewer lives. The AIRE study is the most applicable to current clinical practice but ACE inhibitors should be offered routinely to patients satisfying the criteria of any of the four major clinical trials.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gottlieb S., Moss A. J., McDermott M., Eberly S. Interrelation of left ventricular ejection fraction, pulmonary congestion and outcome in acute myocardial infarction. Am J Cardiol. 1992 Apr 15;69(12):977–984. doi: 10.1016/0002-9149(92)90850-x. [DOI] [PubMed] [Google Scholar]
- Hammermeister K. E., DeRouen T. A., Dodge H. T. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation. 1979 Mar;59(3):421–430. doi: 10.1161/01.cir.59.3.421. [DOI] [PubMed] [Google Scholar]
- McMurray J. ACE inhibitors after myocardial infarction. Lancet. 1993 Dec 4;342(8884):1418–1418. [PubMed] [Google Scholar]
- Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
- Poole-Wilson P. A. ACE inhibitors after myocardial infarction. Lancet. 1994 Jan 29;343(8892):289–290. doi: 10.1016/s0140-6736(94)91134-7. [DOI] [PubMed] [Google Scholar]
- Rowley J. M., Mounser P., Harrison E. A., Skene A. M., Hampton J. R. Management of myocardial infarction: implications for current policy derived from the Nottingham Heart Attack Register. Br Heart J. 1992 Mar;67(3):255–262. doi: 10.1136/hrt.67.3.255. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swedberg K., Held P., Kjekshus J., Rasmussen K., Rydén L., Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) N Engl J Med. 1992 Sep 3;327(10):678–684. doi: 10.1056/NEJM199209033271002. [DOI] [PubMed] [Google Scholar]
- Townend J. N., Littler W. A. Angiotensin converting enzyme inhibitors in heart failure: how good are they? Br Heart J. 1993 May;69(5):373–375. doi: 10.1136/hrt.69.5.373. [DOI] [PMC free article] [PubMed] [Google Scholar]